Article Text

Download PDFPDF
Homocysteine lowering treatment improved outcomes after percutaneous coronary intervention

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 QUESTION: In patients having percutaneous coronary intervention (PCI), does homocysteine lowering treatment with folic acid, vitamin B12, and vitamin B6 reduce adverse coronary outcomes?


Randomised (unclear allocation concealment*), blinded (clinicians, patients, and outcome assessors),* placebo controlled trial with 12 months of follow up.


A university hospital in Bern, Switzerland.


553 patients (mean age 63 y, 80% men) who received angioplasty to treat at least 1 significant coronary stenosis (≥50%). Exclusion criteria were unstable angina, myocardial infarction (MI) within the past 2 weeks, renal insufficiency, or receipt of vitamin supplements. Follow up was 83%; all patients were included in the analysis.


Patients were allocated to homocysteine lowering treatment with folic acid, 1 mg/day; vitamin B12, …

View Full Text


  • For correspondence: Dr G Schnyder, UCSD Medical Center, San Diego, CA, USA. g.schnyder{at}

  • Abstract and commentary also appear in ACP Journal Club.

  • Source of funding: Swiss National Science Foundation.

  • *See glossary.